We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Reprogramming Fibroblasts into Oligodendrocyte Progenitor Cells May Lead to Cure for Multiple Sclerosis and Cerebral Palsy

By LabMedica International staff writers
Posted on 02 May 2013
Working with mouse tissues, investigators have developed a method for converting skin or lung fibroblasts into fully functional oligodendrocytes, the type of cell responsible for myelinating the neurons of the brain and which are lost in myelin disorders such as multiple sclerosis and cerebral palsy.

Cell-based therapies for myelin disorders require technologies to generate functional oligodendrocyte progenitor cells (OPCs). More...
In this regard, investigators at Case Western Reserve School of Medicine (Cleveland, OH, USA) described the direct conversion of mouse embryonic and lung fibroblasts to induced oligodendrocyte progenitor cells (iOPCs) using sets of either three or eight defined transcription factors.

They reported in the April 14, 2013, online edition of the journal Nature Biotechnology that the iOPCs exhibited a bipolar morphology and global gene expression profile consistent with bona fide OPCs. They could be expanded in vitro for at least five passages while retaining the ability to differentiate into multiprocessed oligodendrocytes. When transplanted to hypomyelinated mice, iOPCs were capable of ensheathing host axons and generating compact myelin.

“The myelin repair field has been hampered by an inability to rapidly generate safe and effective sources of functional oligodendrocytes,” said contributing author Dr. Robert Miller, professor of neurosciences at the Case Western Reserve School of Medicine. “The new technique may overcome all of these issues by providing a rapid and streamlined way to directly generate functional myelin producing cells.”

“It is cellular alchemy,” explained senior author Dr. Paul Tesar, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine. “We are taking a readily accessible and abundant cell and completely switching its identity to become a highly valuable cell for therapy.”

Related Links:

Case Western Reserve School of Medicine




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Electrolyte Analyzer
BKE-B
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.